Research on the Correlation Between miRNA, CMTM6, and PD-L1 Expression in Gastric Cancer
Abstract
Objective: To investigate the correlation between miRNA, CMTM6, and PD-L1 expression in gastric cancer, providing new therapeutic targets for immunotherapy in gastric cancer. Methods: This study selected gastric cancer patients who were diagnosed and treated at our hospital from October 2022 to October 2024 as the research subjects. Based on the patients’ PD-L1 examination results, they were divided into a positive group and a negative group. General patient data were collected, and qPCR and WB experiments were used to detect the levels of CMTM6 and miRNA in the patients. Univariate analysis was conducted to identify factors influencing PD-L1 expression, and variables with p < 0.05 were included in multivariate logistic regression analysis to clarify the correlation between miRNA, CMTM6, and PD-L1 expression in gastric cancer. Results: A total of 118 patients were included in this study, with 75 patients in the positive group and 43 patients in the negative group. Univariate analysis revealed that TNM stage, miRNA, and CMTM6 showed statistical significance in data comparison (p < 0.05). These variables were then included in multivariate logistic regression analysis, which found that TNM stage (OR = 2.849, 95% CI: 2.227–3.425), miRNA (OR = 3.038, 95% CI: 2.968–3.509), and CMTM6 (OR = 3.185, 95% CI: 2.995–3.810) all exhibited a positive correlation with PD-L1 expression in gastric cancer. Conclusion: There is a certain correlation between miRNA, CMTM6, and PD-L1 expression in gastric cancer. As miRNA and CMTM6 levels increase, the positive rate of PD-L1 examination in patients also rises, warranting clinical attention.
References
Li J, Ji G, Sun X, et al., 2022, Expression of CMTM6 in Gastric Cancer Tissues and Its Relationship with PD-L1 and Prognosis. Chinese Journal of Clinical Oncology, 27(9): 776–781.
Li L, Ye Z, Wang J, et al., 2023, Expression of CMTM6 and PD-L1 in Gastric Cancer and Its Clinical Significance. Chinese Journal of Clinical and Experimental Pathology, 39(1): 68–73.
Lu J, Li H, Li J, 2025, Study on the Mechanism of Weichang’an in Inhibiting Invasion and Metastasis of Gastric Cancer. World Journal of Integrative Traditional and Western Medicine, 20(1): 61–69.
Yuan M, Guo Z, 2022, Research Progress on Chemokine-Like Factor MARVEL Transmembrane Domain Family Members 4/6 as Regulators of Programmed Death Receptor Ligand 1. Oncology Progress, 20(1): 8–11.
Shi M, Zhang H, Jiang D, 2022, Research Progress on the Relationship and Mechanism of Action Between Gastric Cancer-Related Genes and Immune Biomarkers. Oncology Progress, 20(3): 226–230.
Lv H, Shen H, Zhan B, et al., 2025, Correlation Between PD-L1 Protein Expression and CD8+ Infiltrating Lymphocytes in Gastric Cancer Patients and Its Prognostic Predictive Value. Journal of Difficult and Complicated Cases, 24(5): 532–538 + 544.
Peng S, Xu Z, Yang J, et al., 2025, Correlation Between the Expression of Semaphorin 5A and PD-L1 in Gastric Cancer and Clinicopathological Features. Chinese Journal of Clinical and Experimental Pathology, 41(3): 304–310 + 316.
Xie L, Zhang Z, 2020, Correlation Between the Expression of HER2 and PD-L1 in Gastric Cancer Tissues and Clinicopathological Features. Heilongjiang Medicine Journal, 33(6): 1307–1309.
Mai C, Zhang J, Yan Z, 2025, Correlation Analysis Between the Expression Levels of PD-L1, FBXW7, and HER2 in Tissues of Gastric Cancer Patients and Clinicopathological Features. Sichuan Journal of Physiological Sciences, 47(1): 199–202.
Wu X, Hu N, Zhou K, et al., 2023, Expression of β-Catenin, STT3A, and PD-L1 in Gastric Cancer Tissues and Their Correlation with Pathological Features and Prognosis. Modern Oncology, 31(7): 1270–1275
